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Abstract
Background: Increased expression of the cyclooxygenase-2 enzyme (COX2) is one of the main characteristics of gastric
cancer (GC), which is a leading cause of death in the world, particularly in Asia and South America. Although the Wnt/b-
catenin signaling pathway has been involved in the transcriptional activation of the COX2 gene, the precise mechanism
modulating this response is still unknown.
Methodology/Principal Findings: Here we studied the transcriptional regulation of the COX2 gene in GC cell lines and
assessed whether this phenomenon is modulated by Wnt/b-catenin signaling. We first examined the expression of COX2
mRNA in GC cells and found that there is a differential expression pattern consistent with high levels of nuclear-localized b-
catenin. Pharmacological treatment with either lithium or valproic acid and molecular induction with purified canonical
Wnt3a significantly enhanced COX2 mRNA expression in a dose- and time-dependent manner. Serial deletion of a 1.6 Kbp
COX2 promoter fragment and gain- or loss-of-function experiments allowed us to identify a minimal Wnt/b-catenin
responsive region consisting of 0.8 Kbp of the COX2 promoter (pCOX2-0.8), which showed maximal response in gene-
reporter assays. The activity of this pCOX2-0.8 promoter region was further confirmed by site-directed mutagenesis and
DNA-protein binding assays.
Conclusions/Significance: We conclude that the pCOX2-0.8 minimal promoter contains a novel functional T-cell factor/
lymphoid enhancer factor (TCF/LEF)-response element (TBE Site II; -689/-684) that responds directly to enhanced Wnt/b-
catenin signaling and which may be important for the onset/progression of GC.
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Introduction
Gastric cancer (GC) is a multifactorial disease, characterized by
highly malignant neoplasms in the gastric mucosa, and represents
the second leading cause of cancer death worldwide with the
highest prevalence in Asia and South America [1,2,3]. Environ-
mental associated risk factors include diet, snuff consumption,
obesity and Helicobacter pylori infection [4]. Several mutations in
tumor-suppressor genes, including P53, adenomatous polyposis
coli (APC), E-cadherin and RUNX3 [3,5], as well as in oncogenes
like k-ras, HER2 and b-catenin [3,6,7], have been documented in
GC. In addition, over expression of various genes has been
documented, including WNT2B [8], TC1 (C8orf4) [9], and the
cyclooxygenase 2 (COX2) enzyme, which catalyzes the crucial
step in the production of prostaglandin E2, a key mediator of joint
inflammation [10,11].
It has been observed that the expression of the COX2 gene is
significantly increased in human gastric adenocarcinoma tissues,
when compared with paired gastric mucosal specimens devoid of
cancer cells [10]. Such increased expression has been proposed to
affect the intensity of invasion, size, lymph node metastases, tumor
development and bad prognosis [4,12,13]. In this regard, large
amounts of data describe chemo-preventive and anticancer
activity of non steroidal anti-inflammatory drugs (NSAID)
including selective COX2 inhibitors as potential treatments for
GC [10,11,14].
Transcriptional control of the COX2 gene depends on the
molecular machinery interacting with the COX2 promoter, which
seems to be controlled through the activity of various signaling
pathways [15,16,17]. Indeed, it was initially established that CRE
(259/253), NF-IL6 (2132/2124) and NF-kB( 2233/2214)
consensus sequences in the COX2 promoter were necessary for
the expression of the gene [16]. Subsequent functional studies in
the COX2 promoter identified a series of regulatory elements
participating in the transcription of the gene, including AP-1, AP-
2, Sp-1, C/EBPb [18,19,20] and proteins belonging to the T-Cell
factor/Lymphoid enhancer factor (TCF/LEF) family of transcrip-
tion factors, which are crucial for Wnt/b-catenin signal transduc-
tion [21].
The Wnt/b-catenin signaling pathway is widely acknowledged
as playing a major role in human disease, particularly in the onset
and development of cancer [22,23,24]. Interestingly, recent
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between COX2 expression and the inhibition of the Glycogen
Synthase Kinase-3b (GSK3b) enzyme [25], which is a key Wnt
component that phosphorylates b-catenin and promotes its
subsequent degradation via proteasome [26]. The relationship
between Wnt/b-catenin and COX2 expression in different cancer
cell models is further supported from the following studies. First, it
has been observed in the mammary epithelium that Wnt/b-
catenin play an indirect effect on COX2 transcription, which
could be mediated by up-regulation of an intermediary factor
PEA3 [27]. Second, and in contrast to an indirect mode of action,
Araki and cols. [21] reported that in colon cancer cells there is an
induction in COX2 expression through a b-catenin/TCF
dependent mechanism, and partially characterized a consensus
TCF/LEF binding site (TBE: core CTTTG) positioned 1,079 bp
upstream from the transcriptional start site in the COX2
promoter. Third, it was observed that in colon cancer patients
and derived cell lines there is an association between overexpres-
sion of the Wnt pathway-associated proteins LEF-1 and Pontin52/
TIP49a and up-regulation of COX2 expression [28]. Finally,
using chondrocytes, it has been demonstrated that LEF-1, together
with b-catenin, regulated COX2 expression by direct binding of
the LEF-1/b-catenin complex to the 39UTR region of the COX2
genomic locus [29]. Therefore, at present there is not a clear
picture as to whether Wnt signaling is involved in COX2 gene
expression, or as its role in GC onset/progression. Here we sought
to understand whether there is a direct regulation of the COX2
gene expression via Wnt/b-catenin signaling and to identify Wnt/
b-catenin regulatory elements in the promoter region of the
COX2 gene which can upregulate COX2 transcription in GC
cells.
Materials and Methods
Cells and culture conditions
Human cell-lines MKN45 (Japanese Collection of Research
Bioresources, Japan), N87, SNU1, SNU16, KATOIII, AGS,
WI38 and HEK293 (American Type Culture Collection; Rock-
ville, MD) were used in this study. MKN45, N87, SNU1 and
KATOIII cells were grown in RMPI media (Gibco); AGS in F12K
medium (Hyclone); WI38 in EMEM (Gibco); and HEK293 in
DMEM (Gibco). Culture media was supplemented with 10% FBS
(Gibco) (AGS with 20%) and 1% penicillin/streptomycin. Cell-
lines were maintained at 37uCi n5 %C O 2 and saturated humidity.
Plasmids and site-directed mutagenesis
The SuperTOPFlash-luciferase and the pRL-TK renilla-
luciferase plasmids [30], the constitutive active b-catenin (S33Y)
[31] and the dominant-negative DTCF4 expression plasmids [32]
have been described previously. Chimeric COX2 promoter-
luciferase fragments were generated by PCR from human genomic
DNA using specific primers containing restriction sites and
subsequently inserted into the pGL3-Basic vector (Promega).
The mutations in the TBE-II site (2689/2684) of the COX2
promoter were generated using primers pCOX-0,8-TBEMUT
with the QuickChange site-directed mutagesis kit (Stratagene).
Constructs were verified through direct sequencing (ABI-3130
Genetic Analyzer, Applied Biosystems). Primers sequences are
described in Table S1.
Semiquantitative and Real Time RT-PCR
Total RNA was extracted in RNAse free conditions using
TRIZOL (Invitrogen) and 2 mg of RNA was reverse transcribed
with 200 U of SuperScript II Reverse Transcriptase (RT)
(Invitrogen) using 500 ng of Oligo(dT) primers. Experimental
determination of COX2, c-myc and CCND1 mRNA levels was
performed according to [33]. Briefly, cDNAs were subjected to
Real-Time PCR in an iCycler iQ System (Bio-Rad Laboratories).
Each 25 ml reaction volume contained 1 unit of Platinum Taq
DNA polymerase (Invitrogen), 1X reaction buffer (20 mM Tris-
HCl pH 8.4, and 50 mM KCl), 1.5 mM MgCl2, 2.5 mg BSA,
0.01% Glycerol, 200 mM of dNTPs, 0.3X SYBR Green solution
and 0.4 mM of specific primers (see Table S1). PCR conditions
were set as follows: 90 seconds at 94uC and then 30 cycles of 30
seconds at 94uC, 30 seconds at 62uC and 30 seconds at 72uC. All
reactions were performed in triplicate and results obtained for
each gene were normalized to those obtained in parallel with b-
actin. The quality of RNA and PCR products was monitored
throughout the experiments via electrophoresis on 1% agarose
gels, stained with ethidium bromide.
Induction of the Wnt/b-catenin signaling pathway
Wnt signaling was pharmacologically induced in MKN45 cells
seeded in 6 well culture plates at 80–90% of confluence (i.e. 1, 2, 4
and 8 h of incubation) either with 10–20 mM of LiCl (Sigma) or
5–10 mM of valproic acid (VA; Sigma) as previously described
[34,35]. Then, cells were collected for mRNA extraction and real
time-PCR determination as described above. Similarly, MKN45
cells were stimulated for 2 hours with 200 and 400 ng/ml of
purified Wnt3a protein. Purification of Wnt3a was carried out as
described [36].
Transcriptional activity of the COX2 promoter
Activity of the COX2 promoter was measured in 80–90%
confluent MKN45, AGS, WI38 and HEK293 cells seeded in 6
well culture plates. Briefly, cells were co-transfected using
FUGENE (Roche) for 24 with the pCOX2-luciferase or the
pSuperTOPFlash reporters and either constitutive active b-
catenin (S33Y) [31] or the dominant-negative DTCF4 [32]
constructs. The pRL-TK renilla luciferase plasmid was used as
an internal control. Firefly and renilla luciferase activities were
determined using the Dual-Luciferase Reporter Assay (Promega)
in a Victor-3 multiplate reader instrument (Perkin Elmer), as
described previously [30]. Relative luciferase activities were
expressed by dividing firefly luciferase activity with renilla
luciferase activity for each sample (N=3, each in triplicate).
Chromatin immunoprecipitation (ChIP) assays
ChIP studies were performed in MKN45 cells as described
earlier [37]. The fraction of nuclear b-catenin bound either to
TBE Sites I, II, III or IV in the human COX2 promoter was
immunoprecipitated with anti b-catenin antibodies (Santa Cruz)
and assessed by real time-PCR using specific primers (Table S1).
Additionally, the fraction of the RNA polymerase II (Pol-II) and
acetylated histones H3 and H4 (H3ac and H4ac) bound either to
the TBE-II region (2793/2594) or the proximal region (2118/
+62) of the COX2 promoter was similarly assessed (anti-Pol-II,
Santa Cruz; H3ac and H4ac, Upstate). As a positive control we
used the c-myc TBE site [38]. Antibody specificity was assayed
with normal rabbit-IgG (Santa Cruz).
Electrophoretic mobility shift assay (EMSA)
EMSA was performed using oligonucleotides containing either
the wild-type COX2 TBE-II consensus sequence (see Table S1) or
previously reported mutant TBE sequences [39]. In brief, wild-
type and mutated
32P-labeled oligonucleotides were incubated in
binding buffer with nuclear extracts of MKN-45 cells for 30 min at
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free oligonucleotides on a 5% non denaturating polyacrylamide
gel. After electrophoresis, the gel was dried, and exposed to film
for 1 day. The visualization of radioactive bands was analyzed by
autoradiography. Binding specificity was checked by incubating
the DNA-protein complexes in the presence of an excess of non-
labeled wild-type or mutated oligonucleotides [21,39].
Statistical analysis
Each experiment was repeated at least three times with three
replicates. Data are shown as the mean 6 SD. Multiple group
comparisons were performed by one-way ANOVA using the
STATISTICA 9.0 software. P,0.05 was considered significant.
Results
COX2 expression correlates with nuclear b-catenin levels
in GC cells
We initially determined the expression levels of COX2 mRNA
in human GC cell-lines MKN45, N87, SNU1, SNU16,
KATOIII and AGS [40,41,42], as well as WI38 fibroblasts used
here as a control cell line [43], examining whether they were
correlated with Wnt/b-catenin signaling. As depicted in Figure 1,
strong levels of COX2 expression were observed as early as 26
cycles of PCR amplification in metastatic cell lines MKN45,
SNU16 and KATOIII, and also in the AGS cell line that is
derived from a primary tumor. This result is in agreement with
COX2 expression levels detected previously in MKN45,
KATOIII and AGS cells [44,45,46]. In contrast, COX2 mRNA
levels were either very low in WI38 fibroblasts or undetectable in
N87 and SNU1 cells (Figure 1A), suggesting that this differential
pattern of expression is not related to metastatic stages or the
level of cell transformation. Remarkably, nuclear b-catenin levels
were closely related with COX2 expression, since high levels of
the protein were observed in MKN45, AGS, SNU16 and
KATOIII cells, compared with N87, SNU1 and WI38 cells
(Figure 1B), implying a role for Wnt signaling in COX2 mRNA
expression in GC cells.
Enhancement of COX2 expression via Wnt/b-catenin
signaling
In order to examine if the Wnt cascade is involved in COX2
expression, MKN45 cells were pharmacologically stimulated for
different periods of time (i.e. 1, 2, 4 and 8 h) with either lithium
(LiCl) or valproic acid (VA), since both drugs have been
previously shown to modulate Wnt signaling via inhibition of
GSK3b activity and thus increasing nuclear levels of b-catenin
[34,35]. Interestingly, we observed a marked enhancement of
COX2 expression induced by 10–20 mM LiCl or 5–10 mM VA,
that started soon after incubation with the compounds and which
peaked after two hours of treatment (Figure 2A). Real time
determination of COX2 mRNA levels in MKN45 cells similarly
treated with LiCl or VA (2 h) indicated that COX2 was
significantly up-regulated (Figure 2B) and that this effect was
paralleled with the one observed on Wnt/b-catenin target genes
c-myc [47] and cyclin D1 [48]. Next, in order to rule out the
possibility that the observed phenomenon reflected non-specific
effects of the drugs acting on proteins affecting different signaling
cascades, we applied directly a fully functional purified Wnt3a
protein to MKN45 cells (see Methods). These experiments clearly
showed that 200–400 ng/ml of purified Wnt3a significantly
enhanced COX2 mRNA expression after short periods of
incubation (Figure 2), partially explaining the rapid effect of
LiCl and VA and supporting a direct correlation between
canonical Wnt/b-catenin activation and stimulation of COX-2
transcription in GC cells.
Figure 1. COX2 gene expression and nuclear localization of b-catenin in GC cells. (A) COX2 mRNA expression in control (WI38) and GC cell-
lines (MKN45, AGS, SNU1, SNU16, KATOIII and N87). Total RNA was extracted from cultured cells and semiquantitative RT-PCR was used to determine
COX2 and b-actin RNA levels as an internal control. Twenty-six cycles were chosen as an adequate PCR cycle. (B) Nuclear levels of b-catenin protein in
the same cell-lines, as shown in (A), were examined through Western Blot analysis using nuclear extracts. The TFIIB general transcription factor was
used as an internal control.
doi:10.1371/journal.pone.0018562.g001
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COX2 gene
Previous studies indicated that a Wnt/b-catenin responsive
TBE site (consensus core: CTTTG) is located at 21,079/
21,074 bp upstream from the transcriptional start site (TSS) of
the human COX2 gene [21] (Site IV; Figure 3A, see also Figure
S1). Further scanning of the 1,600 bp upstream sequence from
the TSS [49] allowed us to identify 3 novel putative TBE sites:
2877/2872 bp (Site III; sense orientation), 2689/2684 bp and
2318/2313 bp (Sites II and I, respectively; both in antisense
orientation) (Figure 3A), which are not conserved between the
human and murine COX2 genes (Figure S1). We therefore
cloned the 1,600 bp segment from the human COX2 promoter
(pCOX2), including all four TBE sites, into the pGL3-basic
vector fused to the luciferase gene to be used subsequently in
reporter assays (Figure 3A). Remarkably, paralleled transfection
of 10 ng of this construct in MKN-45 and HEK293 cells revealed
that pCOX2 displayed a significant higher (9-fold) basal
promoter activity in MKN45 cells (Figure 3B and C). We
hypothesized that this higher pCOX2 basal promoter activity
could be related to the elevated content of nuclear b-catenin in
this GC cell line (Figure 1B). Hence, MKN45 and HEK293 cells
were co-transfected with pCOX2 in the presence of lower doses
of a constitutive active b-catenin protein (S33Y) [31]. As observed
Figure 2. Pharmacological and molecular enhancement of COX2 expression via Wnt/b-catenin signaling. (A) COX2 mRNA expression
levels in MKN45 cells treated for 1 to 8 h with either 10–20 mM of lithium (LiCl) or 5–10 mM of Valproic acid (VA) were evaluated through RT-PCR. As
an internal control, b-actin levels were determined. (B) Q-PCR for COX2, c-myc and CCND1 mRNA expression stimulated pharmacologically with
lithium (LiCl) and valproate (VA) during 2 h (top panel). Bottom panel, Q-PCR for COX2 in MKN45 cells stimulated with purified Wnt3a for 2 h. Q-PCR
results were expressed as Relative Quantity (dRn) and b-actin mRNA levels were used as the internal control. Each figure corresponds to at least 3
independent experiments. Statistical significance was determined through ANOVA test (* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0018562.g002
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types, suggesting that b-catenin may bind and then activate
TCF/LEF transcription factors at the functional TBE sites within
the pCOX2 promoter.
Contribution of TBE sites to COX2 promoter activity in GC
cells
To dissect the contribution of Wnt/b-catenin responsive TBE
sites on the transcriptional activity of the COX2 promoter four
pCOX2 deletions constructs were generated: pCOX-1.2
(21,123/+35 bp); pCOX-0.8 (2741/+35 bp); pCOX-0.65
(2582/+35 bp); and pCOX-0.4 (2371/+35 bp) (Figure 4A).
These constructs were subsequently assayed for their activity
through transient transfections in MKN45 and AGS cells, using
the WI38 fibroblasts as a control cell line. Consistent with the
endogenous COX2 expression levels in these GC cell lines
(Figure 1A), pCOX2 deletions retained different levels of activity
in MKN45 and AGS cells (Figure 4B and C). In contrast, no
promoter activity was detected in WI38 fibroblasts (Figure 4D),
even when the transfection doses in these cells were increased 8
fold (i.e. from 50 to 400 ng) (Figure S2). Importantly, and in
agreement with previous reports [50], WI38 cells efficiently
expressed a luciferase-reporter construct containing the promoter
of the p21 gene (Figure S2), indicating that in these control cells
the molecular machinery responsible for inducing COX2
transcription is not active. Further experiments revealed that
transfection in MKN45 and AGS cells with the pCOX2-0.8
construct, which has 859 bp deleted from the 1.6 Kb pCOX2
reporter (Figure 4A), resulted in a significant increase in the
promoter activity when compared with the pCOX2-1.2 reporter
(Figure 4A–C). As no significant differences were observed
between the 1.6 Kb pCOX2 and pCOX2-1.2 constructs (Figure
S3), we did not perform further analyses with the larger construct.
Importantly, pCOX2-0.8 represented the minimum size promoter
Figure 3. Human pCOX2-1.6 promoter activity in response to Wnt/b-catenin signaling. (A) Schematic drawing depicting the genomic
context of ca. 1.6 Kbp from the transcriptional start site (TSS) of the human COX2 promoter, including the location of known transcriptional
regulators (white boxes) and the position of the three novel TCF/LEF-binding elements (TBE: core CTTTG; black boxes) determined in silico.( B&C )
Gene reporter assays in MKN45 (B) and HEK293 (C) cells co-transfected with 10 ng of pCOX2 and increasing concentrations of a constitutively active
b-catenin (S33Y) protein (left panel). Cells were co-transfected with 1 ng of PRL-SV40 Renilla as an internal control. Promoter activity was normalized
as the ratio between firefly luciferase and Renilla luciferase units. RLU: Relative Luciferase Units. Each figure corresponds to at least three independent
experiments. Statistical significance was determined through ANOVA test (* p,0.05, ** p,0.01). Nuclear levels of b-catenin protein were examined in
same cell lines through Western Blot analysis (right panel). The TFIIB general transcription factor was used as an internal control.
doi:10.1371/journal.pone.0018562.g003
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deletion of either 159 or 370 bp from the 59-end, as it is the case
with the pCOX2-0.65 or pCOX2-0.4 constructs, respectively,
decreased more than 2-fold the levels of pCOX2 basal activity.
These results indicate that the region comprised between 0.8 and
0.65 Kbp upstream of the TSS of the COX2 gene, and which
includes a novel TBE response element (TBE Site II; 2689/2684),
may be a key component during the regulation of the basal level of
COX2 gene expression in GC cells.
Upregulation of pCOX2-0.8 via Wnt/b-catenin signaling
We next examined the effect of Wnt/b-catenin signaling at the
novel TBE Site II. We transfected MKN45 cells with the pCOX2-
0.8 reporter construct and co-expressed the constitutive active b-
catenin S33Y protein observing that there was a significant (2-fold)
enhancement of the transcriptional activity of pCOX2-0.8. This b-
catenin-mediated increase was specific since the pCOX2-0.4
construct was not stimulated in this b-catenin over-expression
condition (Figure 5A and B). To control for Wnt/b-catenin
signaling in MKN45 cells we used the Wnt/b-catenin responsive
SuperTOPFLASH (STF) reporter carrying 12 copies of a TBE in
tandem [32], which was transfected alone or in the presence of the
plasmid coding for the mutant b-catenin S33Y protein. Interest-
ingly, while co-expression with the mutant b-catenin S33Y protein
in MKN45 cells was able to enhance (1.9-fold) the activity of the
STF reporter, high levels of basal STF activity were detected in the
absence of the mutant b-catenin (Figure 5C). This result is in
agreement with our previous findings of high levels of endogenous
nuclear b-catenin in this cell-type (see Figure 1B), and confirms
that this nuclear factor is functional. To further confirm this
finding, we performed identical experiments in HEK293 cells and
obtained essentially similar results although in this case a clear
dose-response curve was obtained when pCOX2-0.8 was trans-
fected in the presence of increasing concentrations of the
constitutively active b-catenin S33Y protein (Figure S4). Addi-
tionally, we found that STF activity in HEK293 cells was highly
responsive to the levels of the exogenous mutant b-catenin (Figure
S4C).
To further explore the effects of the Wnt/b-catenin pathway on
the activity of the pCOX2-0.8 we carried out loss-of-function
experiments with a dominant negative TCF4 (DTCF) construct,
which codes for a transcription factor lacking 30 residues from its
amino-terminus and that is unable to bind b-catenin [32]. We
found that in MKN45 cells DTCF expression reduced the high
levels of pCOX2-0.8 basal transcription in a dose-dependent
manner (Figure 5D). This result confirms the key role of TCF/
LEF transcription factors among the regulators of the activity of
the pCOX2-0.8 promoter sequence, and further supports the idea
that the TBE Site II (2689/2684) is involved in the response to
Wnt/b-catenin signaling.
Finally, to directly address the role of the TBE Site II in Wnt/b-
catenin-mediated regulation of the COX2 promoter, we intro-
duced by site-directed mutagenesis a change in 2 key nucleotides
of the consensus sequence of the TBE Site II core (i.e. pCOX2-
0.8: CTTTG; MpCOX2-0.8: CCTCG). These changes have been
shown previously to abolish Wnt/b-catenin-mediated transcrip-
tion [39]. Transient transfection studies revealed that mutation of
the TBE Site II significantly decreased (2–3 fold) the basal activity
of pCOX2-0.8 construct in MKN45 cells (Figure 5E) when
compared with the wild-type pCOX2-0.8 promoter construct.
Moreover, and in agreement to our previous results, mutation of
this TBE site II almost completely blocked b-catenin-mediated
enhancement of the pCOX2-0.8 construct (Figure S4). Taken
together, these results indicate that the TBE Site II (2689/2684)
is a functional component in the COX2 gene transcriptional
regulation.
b-catenin binds to the COX2 gene promoter region
containing the TBE Site II
Because a transcriptionally active conformation of chromatin
structure is reflected by an elevated level of histone acetylation
[51], we precipitated cross-linked chromatin fragments (average
size 300–500 bp) isolated from MKN45 cells using polyclonal
antibodies specific for acetylated histones H3 and H4. Similarly,
Figure 4. pCOX2-0.8 as a minimal COX2 promoter with
maximum basal response in GC cells. (A) Schematic representation
of pCOX2 deletions. (B–D) Gene reporter assay in MKN45 (B), AGS (C)
and WI38 (D) cell lines transiently transfected with 50 ng pCOX
deletions (pCOX2-1.2; pCOX2-0.8; pCOX2-0.65 and pCOX2-0.4) and
50 ng of empty vector. In all experiments cells were transfected with
1 ng of PRL-SV40 Renilla as an internal control. Promoter activity was
normalized as the ratio between firefly luciferase and Renilla luciferase
units. RLU: Relative Luciferase Units. Each figure corresponds to at least
three independent experiments. Statistical significance was determined
through ANOVA test (* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0018562.g004
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normally associated with transcriptional activity. We examined the
enrichment in our precipitates of two promoter sequences: the
proximal promoter (PP) region (2118/+62 from TSS) and the
distal region (2793/2594) of the COX2 promoter containing the
consensus TBE Site II (2689/2684). In particular, the TBE Site
II was targeted since previous experiments indicated preferential
binding of b-catenin to this promoter region (Figure S5). As a
positive control, we evaluated binding at the TBE site in the
promoter of the c-myc gene (21,447/21,144 from TSS), which
was previously described in colon cancer cells [38].
Acetylated histones H3 and H4 and the Polimerase II enzyme
were found to bind within the proximal promoter region
(Figure 6A), indicating that the chromatin structure around the
COX2 promoter in MKN45 cells is in an open conformation, thus
in agreement with our previous results demonstrating that the
COX2 gene is actively transcribing. Notably, the b-catenin protein
was immunoprecipitated from MKN45 samples mostly in
association with the promoter region spanning the 2684/2689
TBE sequence in the COX2 gene (Figure 6B). This factor was
almost undetectable at the proximal promoter region, indicating
that endogenous nuclear b-catenin is primarily recruited to the
TBE Site II in these GC cells. As expected, endogenous b-catenin
was similarly bound to the c-myc promoter TBE site, at levels that
are comparable to those observed in the COX2 gene promoter
(Figure 6C).
Collectively, these experiments indicate that the TBE Site II is
directly involved in b-catenin-mediated transcriptional activation
of the COX2 promoter. To further confirm these results we
performed electrophoretic mobility shift assays (EMSA) in nuclear
extracts of MKN45 cells. For this purpose we prepared 34 based-
paired oligonucleotides; one containing the wild-type 2689/2684
TBE Site II sequence (i.e. CTACAAAGA; residues underlined
representing the core), and two oligonucleotides containing
missense mutations in either the core of the TBE Site II (i.e.
CTACGAGGA: TBE-MUT1) or in the flanking sequence (i.e.
CGCCAAAGA: TBE-MUT2), as reported previously [21,39]. As
shown in Figure 6D, the radiolabeled wild-type TBE probe was
capable to form retarded DNA-protein complexes when incubated
with nuclear extracts from MKN45 cells. These protein-DNA
complexes were specific since the addition of an excess of cold
wild-type oligonucleotides (50-fold) dramatically inhibited the
formation of the DNA-protein complex (Figure 6D, lane 3 and
4, respectively). The mutant radiolabeled TBE-MUT1 probe was
neither able to form DNA-protein complexes on its own, nor to
compete with the wild-type oligonucleotide when added in excess
as a cold probe (Figure 6D, lane 5 and 6, respectively). Similar
results were obtained when the second cold TBE-MUT2 probe
was used as a competitor (Figure 6D, lane 7). Altogether, these
results demonstrate that the novel TBE Site II in the COX2
promoter is involved in the transcriptional activation of the COX2
gene by recruiting the machinery responsible for transducing
Wnt/b-catenin signaling (Figure 6E).
Discussion
Previous studies have suggested a role for Wnt/b-catenin
signaling during the onset and/or development of various types of
cancer via modulating the expression of the COX2 gene [25]. In
this work we have presented strong evidence supporting a direct
role for Wnt/b-catenin signaling in the control of COX2
expression in GC cells. First, we have shown that there is a tight
Figure 5. Wnt/b-catenin signaling modulates pCOX2-0.8 activity in MKN45 cells. Gene reporter assays in MKN45 cells transiently
transfected with either 10 ng pCOX2-0.8 (A) or pCOX2-0.4 (B), plus 5–10 ng of b-catenin S33Y and 10 ng of empty vector as control. (C)
SuperTOPFlash (STF; 10 ng) was co-transfected with 10 ng of b-catenin S33Y as a positive control for Wnt/b-catenin signaling activity. (D) Effect of a
dominant negative TCF-4 (DTCF) construct on the activity of pCOX2-0.8. MKN45 cells were transiently co-transfected with 50 ng pCOX2-0.8 and 20–
50 ng of DTCF. (E) Comparison between the activity of the wild-type pCOX2-0.8 and a mutant MpCOX2-0.8 construct, containing mutated residues in
the TBE Site II in the pCOX2-0.8 promoter as background. Cells were transfected with increasing concentrations of pCOX2-0.8, MpCOX-08, or equal
amounts of empty vector as a control. In all experiments 1 ng of PRL-SV40 Renilla was transfected as an internal control. Promoter activity was
normalized as the ratio between firefly luciferase and Renilla luciferase units. RLU: Relative Luciferase Units. Each figure corresponds to at least three
independent experiments. Statistical significance was determined through ANOVA test (* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0018562.g005
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b-catenin, which seems to be independent of either malignancy or
transformation state of CG cells. Second, time- and dose-
dependent enhancement of COX2 expression was observed soon
after induction (2 h) with either pharmacological compounds
mimicking Wnt/b-catenin signaling. Third, gene reporter assays
evaluating the COX2 promoter activity in response to gain- and
loss-of-function experiments, including a constitutively active b-
catenin protein and dominant negative TCF4 transcription factor,
demonstrate that Wnt/b-catenin components are involved in the
transcriptional regulation of the COX2 gene.
We have also shown here that within 2 Kbp upstream of the
human COX2 promoter there are four putative TBE sites (core:
CTTTG), one of which has been previously studied by Araki and
cols [21,28]. Through gene reporter assays with different pCOX2
deletion constructs we showed that pCOX2-0.8 displayed the
highest basal transcriptional activity in the GC cells MKN45 and
AGS. Interestingly, pCOX2-0.8 maintained the TBE Site-II
(2689/2684) integrity indicating its key contribution to the
regulation of the transcriptional activity of the COX2 gene.
Notably, the complete pCOX2 TBE Site II signature (i.e. 59-
WWCAAAGS-39; S=C/G; W=A/T), resembles the optimal
Figure 6. Binding of b-catenin to the TBE Site II (2689/2684) in the COX2 promoter. (A–C) ChIP assays in MKN45 cells using specific
antibodies for b-catenin (b-cat), polymerase II (Pol), H3 and H4 acetylated histones (H3ac; H4ac) and immunoglobulin G (IgG). Quantification was
done by real time PCR using specific primers for the proximal promoter (PP) region (A), the TBE Site II (2689/2684) in the human COX2 promoter (B)
and a TBE site within the c-myc promoter, as a positive control (C). (D) EMSA assay in nuclear extracts from MKN45 cells. DNA-protein complexes
formed by incubating nuclear extracts (N.E.) from MKN45 cells with radiolabelled probes containing the intact and a mutated TBE Site II (lanes 3 and
5) were resolved in native polyacrylamide gels at 5% and revealed through autoradiography. To determine the specificity of the binding a 50 times
excess of non-radiolabelled wild-type (line 4) and mutant (6 and 7) oligonucleotides were added. Lanes 1 and 2 correspond to the wild-type and
mutant radiolabelled oligonucleotides without incubation with N.E. These tests are representative of three independent experiments. E. Model
depicting the molecular mechanism by which Wnt/b-catenin signaling may contribute to the expression of the human COX2 gene.
doi:10.1371/journal.pone.0018562.g006
Wnt/b-Catenin Signaling Enhances COX2 Expression
PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e18562TCF site described by van de Wetering and cols. [52], which was
subsequently used to identify genuine Wnt-transcriptional targets
in the Drosophila genes nkd and CG6234 [53].
Functionality of this TBE Site II was also confirmed by our
mutagenesis studies. Thus, when we mutated the TBE-signature
sequence into the pCOX2-0.8 construct (MpCOX2-0.8), it was
found that basal COX2 promoter activity was significantly
affected in MKN45 cells. In addition our ChIP and EMSA
analyses confirmed that b-catenin is preferentially recruited to the
2689/2684 COX2 promoter region in GC cells, at a level that
resembles that found at the c-myc promoter [38]. Such interaction
preferentially occurs on this region of the COX2 gene promoter as
no b-catenin is found to bind to the proximal promoter region of
the COX2 gene. Altogether these results indicate that the TBE
Site II is a functional Wnt/b-catenin responsive element within the
human COX2 promoter. Our data, nevertheless, does not rule out
the contribution of other genomic regions in the human COX2
gene [21]. Instead, we propose that in GC cells a complex web of
interactions is present where the TBE Site II cooperates with other
response elements to up-regulate COX2 expression.
As our results in GC cells are in agreement with those reported
for colon cancer cells, it is tempting to speculate that Wnt/b-catenin
signaling could be similarly involved in COX2 regulation in other
tumors [21,28]. Indeed, moderate to strong protein levels of b-
catenin can be observed in ca. 72% of all cancers analyzed in the
Human Atlas Protein tissue database [54]. Similarly, strong to
moderate cytoplasmic COX2 staining and occasional membranous
reactivity is observed in 50% of all cancers, including colorectal,
prostate, cervical, endometrial, urothelial, pancreatic, liver and in
glandular cells from gastric tumor tissue. Interestingly, simultaneous
detection of COX2 and b-catenin immunoreactivity in these GC
tumorsisobservedin8outof12identical individuals(Figure S6and
Table S2), arguing in favor of a positive relationship between
COX2 expression and the intracellular levels of the b-catenin
protein, and thus the activity of the canonical Wnt signaling
pathway in the transcriptional regulation of the COX2 gene.
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